612 related articles for article (PubMed ID: 1575457)
1. Striatal D2 receptor status in patients with Parkinson's disease, striatonigral degeneration, and progressive supranuclear palsy, measured with 11C-raclopride and positron emission tomography.
Brooks DJ; Ibanez V; Sawle GV; Playford ED; Quinn N; Mathias CJ; Lees AJ; Marsden CD; Bannister R; Frackowiak RS
Ann Neurol; 1992 Feb; 31(2):184-92. PubMed ID: 1575457
[TBL] [Abstract][Full Text] [Related]
2. Differing patterns of striatal 18F-dopa uptake in Parkinson's disease, multiple system atrophy, and progressive supranuclear palsy.
Brooks DJ; Ibanez V; Sawle GV; Quinn N; Lees AJ; Mathias CJ; Bannister R; Marsden CD; Frackowiak RS
Ann Neurol; 1990 Oct; 28(4):547-55. PubMed ID: 2132742
[TBL] [Abstract][Full Text] [Related]
3. Long-term changes of striatal dopamine D2 receptors in patients with Parkinson's disease: a study with positron emission tomography and [11C]raclopride.
Antonini A; Schwarz J; Oertel WH; Pogarell O; Leenders KL
Mov Disord; 1997 Jan; 12(1):33-8. PubMed ID: 8990051
[TBL] [Abstract][Full Text] [Related]
4. Levodopa-induced changes in synaptic dopamine in patients with Parkinson's disease as measured by [11C]raclopride displacement and PET.
Tedroff J; Pedersen M; Aquilonius SM; Hartvig P; Jacobsson G; Långström B
Neurology; 1996 May; 46(5):1430-6. PubMed ID: 8628494
[TBL] [Abstract][Full Text] [Related]
5. [11C]raclopride and positron emission tomography in previously untreated patients with Parkinson's disease: Influence of L-dopa and lisuride therapy on striatal dopamine D2-receptors.
Antonini A; Schwarz J; Oertel WH; Beer HF; Madeja UD; Leenders KL
Neurology; 1994 Jul; 44(7):1325-9. PubMed ID: 8035939
[TBL] [Abstract][Full Text] [Related]
6. Striatal opioid receptor binding in Parkinson's disease, striatonigral degeneration and Steele-Richardson-Olszewski syndrome, A [11C]diprenorphine PET study.
Burn DJ; Rinne JO; Quinn NP; Lees AJ; Marsden CD; Brooks DJ
Brain; 1995 Aug; 118 ( Pt 4)():951-8. PubMed ID: 7655890
[TBL] [Abstract][Full Text] [Related]
7. Complementary positron emission tomographic studies of the striatal dopaminergic system in Parkinson's disease.
Antonini A; Vontobel P; Psylla M; Günther I; Maguire PR; Missimer J; Leenders KL
Arch Neurol; 1995 Dec; 52(12):1183-90. PubMed ID: 7492293
[TBL] [Abstract][Full Text] [Related]
8. Differential patterns of dopamine transporter loss in the basal ganglia of progressive supranuclear palsy and Parkinson's disease: analysis with [(123)I]IPT single photon emission computed tomography.
Im JH; Chung SJ; Kim JS; Lee MC
J Neurol Sci; 2006 May; 244(1-2):103-9. PubMed ID: 16473371
[TBL] [Abstract][Full Text] [Related]
9. Presynaptic and postsynaptic striatal dopaminergic function in neuroacanthocytosis: a positron emission tomographic study.
Brooks DJ; Ibanez V; Playford ED; Sawle GV; Leigh PN; Kocen RS; Harding AE; Marsden CD
Ann Neurol; 1991 Aug; 30(2):166-71. PubMed ID: 1897909
[TBL] [Abstract][Full Text] [Related]
10. Slower progression of Parkinson's disease with ropinirole versus levodopa: The REAL-PET study.
Whone AL; Watts RL; Stoessl AJ; Davis M; Reske S; Nahmias C; Lang AE; Rascol O; Ribeiro MJ; Remy P; Poewe WH; Hauser RA; Brooks DJ;
Ann Neurol; 2003 Jul; 54(1):93-101. PubMed ID: 12838524
[TBL] [Abstract][Full Text] [Related]
11. Subregional patterns of preferential striatal dopamine transporter loss differ in Parkinson disease, progressive supranuclear palsy, and multiple-system atrophy.
Oh M; Kim JS; Kim JY; Shin KH; Park SH; Kim HO; Moon DH; Oh SJ; Chung SJ; Lee CS
J Nucl Med; 2012 Mar; 53(3):399-406. PubMed ID: 22323779
[TBL] [Abstract][Full Text] [Related]
12. Measurement of the dopaminergic degeneration in Parkinson's disease with [123I] beta-CIT and SPECT. Correlation with clinical findings and comparison with multiple system atrophy and progressive supranuclear palsy.
Brücke T; Asenbaum S; Pirker W; Djamshidian S; Wenger S; Wöber C; Müller C; Podreka I
J Neural Transm Suppl; 1997; 50():9-24. PubMed ID: 9120429
[TBL] [Abstract][Full Text] [Related]
13. Attenuation of fluctuating striatal synaptic dopamine levels in patients with Parkinson disease in response to subthalamic nucleus stimulation: a positron emission tomography study.
Nimura T; Yamaguchi K; Ando T; Shibuya S; Oikawa T; Nakagawa A; Shirane R; Itoh M; Tominaga T
J Neurosurg; 2005 Dec; 103(6):968-73. PubMed ID: 16381182
[TBL] [Abstract][Full Text] [Related]
14. Increased density of dopamine D2 receptors in the putamen, but not in the caudate nucleus in early Parkinson's disease: a PET study with [11C]raclopride.
Rinne JO; Laihinen A; Ruottinen H; Ruotsalainen U; Någren K; Lehikoinen P; Oikonen V; Rinne UK
J Neurol Sci; 1995 Oct; 132(2):156-61. PubMed ID: 8543941
[TBL] [Abstract][Full Text] [Related]
15. In vivo studies on striatal dopamine D1 and D2 site binding in L-dopa-treated Parkinson's disease patients with and without dyskinesias.
Turjanski N; Lees AJ; Brooks DJ
Neurology; 1997 Sep; 49(3):717-23. PubMed ID: 9305330
[TBL] [Abstract][Full Text] [Related]
16. Striatal and Extrastriatal Monoaminergic Disruption in Progressive Supranuclear Palsy.
Ma JH; Dong C; Qiao HW; Barret O; Tamagnan GD; Mao W; Xu EH; Zhang C; Lu J; Chan P; Liu SY
Mov Disord; 2024 May; 39(5):847-854. PubMed ID: 38477228
[TBL] [Abstract][Full Text] [Related]
17. Upregulation of putaminal dopamine D2 receptors in early Parkinson's disease: a comparative PET study with [11C] raclopride and [11C]N-methylspiperone.
Kaasinen V; Ruottinen HM; Någren K; Lehikoinen P; Oikonen V; Rinne JO
J Nucl Med; 2000 Jan; 41(1):65-70. PubMed ID: 10647606
[TBL] [Abstract][Full Text] [Related]
18. D2 receptor binding in dopa-responsive dystonia.
Künig G; Leenders KL; Antonini A; Vontobel P; Weindl A; Meinck HM
Ann Neurol; 1998 Nov; 44(5):758-62. PubMed ID: 9818931
[TBL] [Abstract][Full Text] [Related]
19. 123I-Ioflupane/SPECT binding to striatal dopamine transporter (DAT) uptake in patients with Parkinson's disease, multiple system atrophy, and progressive supranuclear palsy.
Antonini A; Benti R; De Notaris R; Tesei S; Zecchinelli A; Sacilotto G; Meucci N; Canesi M; Mariani C; Pezzoli G; Gerundini P
Neurol Sci; 2003 Oct; 24(3):149-50. PubMed ID: 14598060
[TBL] [Abstract][Full Text] [Related]
20. Presynaptic and postsynaptic dopaminergic binding densities in the nigrostriatal and mesocortical systems in early Parkinson's disease: a double-tracer positron emission tomography study.
Ouchi Y; Kanno T; Okada H; Yoshikawa E; Futatsubashi M; Nobezawa S; Torizuka T; Sakamoto M
Ann Neurol; 1999 Nov; 46(5):723-31. PubMed ID: 10553989
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
